An experimental blood test developed at UCLA that uses gene activity data from immune cells was 93 percent accurate in predicting survival rates for people with advanced heart failure who had surgery to implant mechanical circulatory support devices.
Mechanical circulatory support devices, such as ventricular assist devices and temporary total artificial hearts, can be surgically implanted in people with advanced heart failure to help the heart’s pumping function.
But people with advanced heart failure often also suffer from multi-organ dysfunction syndrome, which can lead to death after a device is implanted and is associated with atypical white blood cell activity. When patients and doctors are considering a mechanical assist device, current clinical methods used to predict treatment results have limitations: They do not perform well in very sick patients and they do not use molecular information. That lack of precision in predicting treatment outcomes can complicate the shared decision-making process between patients and their doctors.
Dr. Mario Deng, the study’s principal investigator, was also a co-developer of an FDA-approved molecular blood test called AlloMap, which is used to diagnose organ rejection in heart transplant recipients. The technology used in the new study, called MyLeukoMap, builds on the methods used in developing AlloMap.
The study involved 29 people with advanced heart failure who underwent mechanical circulatory support surgery at UCLA from 2012 to 2014. Researchers collected blood samples one day before surgery and took clinical data both before surgery and eight days afterward.
The patients were classified into two groups depending on their level of organ function. Seventeen patients showed improvement and 12 did not. One year later, 88 percent of the people in the “improved” group were still alive, compared with 27 percent in the other group.
The researchers identified a set of 28 genes from the pre-surgery blood samples that predicted how well the patients’ organ function would recover shortly after surgery — and of those 28 genes, 12 helped predict whether organ function would improve after surgery and in forecasting whether the patients would live at least a year after the surgery.
The researchers hope to study whether the test can also be used to accurately predict how people with advanced heart failure and declining organ function will fare after undergoing other types of heart surgery and catheter-based interventions. The test also could help patients and doctors make more informed decisions about treatment options — if it predicts a poor outcome, patients could choose to postpone surgery until their condition improves or could opt for another course of treatment. Ultimately, it could improve survival rates, and the quality and cost-effectiveness of care.
In the next phase of the study, researchers will expand the research to analyze results for 1,000 patients from 10 sites in the U.S. and around the world.
The study was led by Deng, a professor of medicine in the division of cardiology at the David Geffen School of Medicine at UCLA. Co-authors from UCLA are Dr. Galyna Bondar, Ryan Togashi, Dr. Martin Cadeiras, Dr. Joanna Schaenman, Lindsay Masukawa, Josephine Hai, Tra-Mi Bao, Desai Chu, Eleanor Chang, Maral Bakir, Victoria Groysberg, Dr. Tristan Grogan, Dr. Joseph Meltzer, Dr. Murray Kwon, Dr. Maura Rossetti, Dr. David Elashoff, Dr. Elaine Reed and Dr. Pei Pei Ping. Other co-authors are Dr. Richard K. Cheng of University of Washington Medical Center and Sophie Kupiec-Weglinski of Cornell University.
The study was published Dec. 13 in the Journal PLOS ONE.
The work was supported by the department of medicine at the David Geffen School of Medicine at UCLA and by the National Institutes of Health. The authors have no financial interests to disclose.
Learn more about the cardiovascular research theme at UCLA.
MEDIA CONTACTRegister for reporter access to contact details